CytomX Therapeutics's total assets for Q3 2025 were $158.25M, a decrease of -9.60% from the previous quarter. CTMX total liabilities were $50.87M for the fiscal quarter, a -7.76% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.